440 related articles for article (PubMed ID: 34312098)
1. Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients.
He X; Dai X; Ji J; Liu H; Shi G; Yeung SJ
Clin Breast Cancer; 2022 Jan; 22(1):e80-e90. PubMed ID: 34312098
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.
Bayraktar S; Gonzalez-Angulo AM; Lei X; Buzdar AU; Valero V; Melhem-Bertrandt A; Kuerer HM; Hortobagyi GN; Sahin AA; Meric-Bernstam F
Cancer; 2012 May; 118(9):2385-93. PubMed ID: 21953213
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Ginzac A; Molnar I; Durando X; Motte Rouge T; Petit T; D'hondt V; Campone M; Bonichon-Lamichhane N; Venat Bouvet L; Levy C; Augereau P; Pistilli B; Arsene O; Jouannaud C; Nguyen S; Cayre A; Tixier L; Mahier Ait Oukhatar C; Nabholtz JM; Penault-Llorca F; Mouret-Reynier MA
Breast Cancer Res Treat; 2024 Jun; 205(2):267-279. PubMed ID: 38453781
[TBL] [Abstract][Full Text] [Related]
4. Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.
Ueno T; Masuda N; Sato N; Ohtani S; Yamamura J; Matsunami N; Kashiwaba M; Takano T; Takahashi M; Kaneko K; Ohno S; Morita S; Toi M
Jpn J Clin Oncol; 2020 Jan; 50(1):3-11. PubMed ID: 31821506
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer.
Gupta A; Gogia A; Deo S; Sharma DN; Mathur S; Sagiraju HKR
Cancer Treat Res Commun; 2023; 36():100741. PubMed ID: 37453371
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
[TBL] [Abstract][Full Text] [Related]
7. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K
Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459
[TBL] [Abstract][Full Text] [Related]
8. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.
Swain SM; Ewer MS; Viale G; Delaloge S; Ferrero JM; Verrill M; Colomer R; Vieira C; Werner TL; Douthwaite H; Bradley D; Waldron-Lynch M; Kiermaier A; Eng-Wong J; Dang C;
Ann Oncol; 2018 Mar; 29(3):646-653. PubMed ID: 29253081
[TBL] [Abstract][Full Text] [Related]
9. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial.
Papakonstantinou A; Matikas A; Bengtsson NO; Malmström P; Hedayati E; Steger G; Untch M; Hübbert L; Johansson H; Hellström M; Gnant M; Loibl S; Greil R; Moebus V; Foukakis T; Bergh J
Cancer; 2020 Mar; 126(6):1175-1182. PubMed ID: 31851385
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.
Schneeweiss A; Chia S; Hickish T; Harvey V; Eniu A; Waldron-Lynch M; Eng-Wong J; Kirk S; Cortés J
Eur J Cancer; 2018 Jan; 89():27-35. PubMed ID: 29223479
[TBL] [Abstract][Full Text] [Related]
12. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
[TBL] [Abstract][Full Text] [Related]
13. Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: An Indian experience.
Tiwari A; Gogia A; Deo S; Shukla NK; Mathur S; Sharma DN
Indian J Cancer; 2017; 54(1):343-346. PubMed ID: 29199719
[TBL] [Abstract][Full Text] [Related]
14. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
15. Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-Up of Prognostic Study Using Propensity Score Matching.
Fujita N; Fujita K; Kim SJ; Iguchi C; Nomura T; Aono T; Yanagisawa T; Enomoto Y; Inakami K; Miyagawa Y; Tomoike R; Kasugai T; Shiba E
Oncology; 2022; 100(5):257-266. PubMed ID: 35114682
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant trastuzumab in HER2-positive breast cancer.
Slamon D; Eiermann W; Robert N; Pienkowski T; Martin M; Press M; Mackey J; Glaspy J; Chan A; Pawlicki M; Pinter T; Valero V; Liu MC; Sauter G; von Minckwitz G; Visco F; Bee V; Buyse M; Bendahmane B; Tabah-Fisch I; Lindsay MA; Riva A; Crown J;
N Engl J Med; 2011 Oct; 365(14):1273-83. PubMed ID: 21991949
[TBL] [Abstract][Full Text] [Related]
17. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
Huober J; Holmes E; Baselga J; de Azambuja E; Untch M; Fumagalli D; Sarp S; Lang I; Smith I; Boyle F; Xu B; Lecocq C; Wildiers H; Jouannaud C; Hackman J; Dasappa L; Ciruelos E; Toral Pena JC; Adamchuk H; Hickish T; de la Pena L; Jackisch C; Gelber RD; Piccart-Gebhart M; Di Cosimo S
Eur J Cancer; 2019 Sep; 118():169-177. PubMed ID: 31377477
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer.
Li S; Wei W; Jiang Y; Li Q; Huang Q; Yang H; Liu J
Drug Des Devel Ther; 2018; 12():3085-3093. PubMed ID: 30275685
[TBL] [Abstract][Full Text] [Related]
19. Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial.
Conte B; Montemurro F; Levaggi A; Blondeaux E; Molinelli C; Cardinali B; Poggio F; Buzzatti G; Bighin C; Lambertini M; Del Mastro L
Tumori; 2023 Feb; 109(1):71-78. PubMed ID: 34989265
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
Lavasani SM; Somlo G; Yost SE; Frankel PH; Ruel C; Cui Y; Murga M; Tang A; Martinez N; Kruper L; Tumyan L; Schmolze D; Yeon C; Yuan Y; Waisman JR; Mortimer J
Cancer; 2023 Mar; 129(5):740-749. PubMed ID: 36517940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]